Exhibit 10.328

|CONFIDENTIAL |  | REDACTED VERSION
|------------ |  | ----------------

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

***CONFIDENTIAL TREATMENT REQUESTED***

FUTURE BLOOD SCREENING ASSAY        WEST NILE VIRUS ADDENDUM        AMENDING        AGREEMENT ENTERED INTO AS OF JUNE 11, 1998        BY AND BETWEEN        GEN-PROBE INCORPORATED, A DELAWARE CORPORATION        AND        CHIRON CORPORATION

---



TABLE OF CONTENTS

|                              |  | Page                                              
|----------------------------- |  | --------------------------------------------------
|1.    Definitions             |  | 2                                                 
|                              |  | 1.1    Agreement                                  
|                              |  | 1.2    Alternative NAT Clinical Diagnostic Product
|                              |  | 1.3    Binder                                     
|                              |  | 1.4    Budget                                     
|                              |  | 1.5    Completion Date                            
|                              |  | 1.6    FTE Labor Rate                             
|                              |  | 1.7    Interim Events                             
|                              |  | 1.8    Material Modification                      
|                              |  | 1.9    NIH Monies                                 
|                              |  | 1.10    Non-material Modification                 
|                              |  | 1.11    Product Requirements Document             
|                              |  | 1.12    Project Management                        
|                              |  | 1.13    Resource Plan                             
|                              |  | 1.14    Software Requirements Specifications      
|                              |  | 1.15    Technical Plan                            
|                              |  | 1.16    Timeline                                  
|                              |  | 1.17    WNV Assay Product                         
|                              |  | 1.18    WNV Development Costs                     
|                              |  | 1.19    WNV Development Program                   
|                              |  | 1.20    WNV Clinical Diagnostic Product           
|2.    WNV Development Program |  | 3                                                 
|                              |  | 2.1    Objective                                  
|                              |  | 2.2    General Conduct of Development             
|                              |  | 2.3    No Guarantee                               
|                              |  | 2.4    Project Management                         
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  | 2.5    Development Responsibilities               
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   
|                              |  |                                                   

i

---

|3.    Modifications                                      |  | 8                                                                            
|-------------------------------------------------------- |  | -----------------------------------------------------------------------------
|                                                         |  | 3.1    WNV Development Program Definition                                    
|                                                         |  | 3.2    Modifications                                                         
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 3.3    Material Modifications                                                
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 3.4    Notice of Significant Changes                                         
|4.    Changes to WNV Assay Product after Completion Date |  | 10                                                                           
|                                                         |  | 4.1    Process                                                               
|                                                         |  | 4.2    Additional Work under Addendum                                        
|5.    WNV Development Costs                              |  | 11                                                                           
|                                                         |  | 5.1    [***] WNV Development Costs                                           
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 5.2    Definition and Calculation of WNV Development Costs                   
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 5.3    Payment of WNV Development Costs                                      
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 5.4    Additional Provisions regarding Shared Revenues                       
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 5.5    Dispute                                                               
|                                                         |  | 5.6    Right to Audit and Verify                                             
|6.    Manufacturing and Commercialization                |  | 15                                                                           
|                                                         |  | 6.1    Definitions Relevant to Manufacturing and Commercialization Obligation
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  |                                                                              
|                                                         |  | 6.2    Right to Audit and Verify                                             
|                                                         |  | 6.3    Non-Commercial Products                                               
|                                                         |  | 6.4    Commercialization Budget                                              
|7.    License Grants                                     |  | 17                                                                           
|                                                         |  |                                                                              

ii

---

|8.    Addendum Effective Date; Term; Termination |  | 18                                                                                          
|------------------------------------------------ |  | --------------------------------------------------------------------------------------------
|                                                 |  |                                                                                             
|                                                 |  | 8.1    Termination for Breach                                                               
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  | 8.2    Termination by Both Parties                                                          
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  | 8.3    Termination by Either Party; Unilateral Withdrawal from WNV Development Program      
|                                                 |  | 8.4    Continuance of WNV Development Program following Unilateral Withdrawal or Termination
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|                                                 |  |                                                                                             
|9.    Escalation                                 |  | 22                                                                                          
|                                                 |  | 9.1    Escalation Process                                                                   
|                                                 |  | 9.2    Remedies in Event of Default                                                         
|                                                 |  | 9.3    Survival                                                                             
|10.    No Other Amendment                        |  | 22                                                                                          
|11.    Counterparts                              |  | 23                                                                                          

iii

---

Future Blood Screening Assay

WEST NILE VIRUS ADDENDUM

This Future Blood Screening AssayWest Nile Virus Addendum (the "West Nile Virus Addendum") is entered into, effective as of June 1, 2003 (the
"Addendum Effective Date") pursuant to and amending that certain Agreement entered into as of June 11, 1998 (the "Agreement") by and between Gen-Probe Incorporated, a Delaware
corporation ("Gen-Probe") with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation ("Chiron;" collectively with
Gen-Probe, the "parties") with a place of business at 4560 Horton Street, Emeryville, CA 94608.

Recitals

A.    The
parties entered into the Agreement as of June 11, 1998. The Agreement was amended by the following: (i) June 11, 1998 Supplemental letter
agreement, (ii) June 26, 1998 Addendum to Collaboration Agreement, (iii) June 30, 1998 Supplemental letter agreement, (iv) June 30, 1998 Consent,
(v) December 7, 1999 Amendment to Collaboration Agreement, (vi) February 1, 2000 Amendment No. 2 to Collaboration Agreement, (vii) June 7, 2001
Supplemental agreement no. 1 (Customer training and Support), (viii) October 30, 2001 Confidentiality and Joint Interest Agreement, and (ix) April 1, 2002 Amendment
No. 3 (warehousing and shipping). In addition, the parties entered into certain settlements, described in Recital E below.

B.    In
the Agreement, the parties agreed to discuss, during the term thereof, the selection and establishment of one or more Development Programs for one or more Future Blood
Screening Assays to be conducted by the Blood Screening Instruments.

C.    The
parties have discussed a proposed development of an assay for the detection of West Nile Virus (WNV), on a semi-automated instrument system, which assay
would fall within the definition of a "Future Blood Screening Assay" set forth in Section 1.30 of the Agreement and does not include HCV as a constituent element.

D.    Gen-Probe
applied for and received a contract with the National Institutes of Health, Contract No. NO1-HB-07148, effective
January 1, 2000, which contract as amended provides for, among other things, the partial funding of costs associated with the development of the WNV Assay Product.

E.    The
parties submitted a number of disputes under the Agreement to arbitration pursuant to Section 13 of the Agreement, and in resolution of those disputes,
executed a Definitive Written Settlement Agreement, dated December 5, 2001, and a Short Form Agreement, dated November 16, 2001. All provisions of these settlement agreements which
address the subject matter addressed in this Addendum are expressly superceded by this West Nile Virus Addendum, except as expressly described herein.

F.     By
this West Nile Virus Addendum, the parties desire to include the West Nile Virus Assay to be conducted by one or more of the Blood Screening Instruments within the
scope of the provisions of the Agreement as clarified and amended by the terms and conditions more particularly described in this West Nile Virus Addendum.

G.    The
purpose of WNV development program is to meet an urgent need in the United States, as articulated by FDA and industry, to provide an IND WNV screening assay by
July 1, 2003. The parties intend that, if a fully licensed product becomes required and commercially appropriate, the terms applicable to the development and distribution of that product will
require a modification of this Agreement.

---

Agreement

NOW, THEREFORE, for and in consideration of the mutual covenants and agreements set forth in this West Nile Virus Addendum, the parties agree as follows:

1.Definitions.All capitalized terms used but not defined in this West Nile Virus Addendum shall have the
meanings set forth in the Agreement.



2

---



2.WNV Development Program.



3

---



4

---



5

---



6

---







Function

Principal Responsibility

Shared Responsibility[***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]



[***][***]



[***][***]

[***][***]



[***][***]

[***][***]



[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]

[***][***]



[***]


---



7

---



3.Modifications.



8

---



9

---



4.Changes to WNV Assay Product after Completion Date.



10

---



5.WNV Development Costs.



11

---



12

---



13

---



14

---



6.Manufacturing and Commercialization.



15

---







16

---



7.License Grants.

The
grant of licenses for the purpose of conducting the WNV Development Program shall be governed by Sections 3.2.6 and Section 9 of the Agreement. For the avoidance of doubt,
Chiron confirms that Gen-Probe shall be [***].

17

---

8.Addendum Effective Date; Term; Termination.

Term of West Nile Virus Addendum.This West Nile Virus Addendum shall become effective on the Addendum Effective Date and
shall continue in effect through the Blood Screening Term, unless sooner terminated in accordance with the provisions hereof. For the avoidance of doubt, the parties reiterate that the WNV Assay
Product to be developed under this Addendum constitutes a Future Blood Screening Assay pursuant to the Agreement. Termination of this West Nile Virus Addendum prior to the expiration of the Blood
Screening Term shall be governed by the terms of this Section and termination of the Agreement shall be governed by Section 11.2 of the Agreement.



18

---



The
withdrawing party may terminate this West Nile Virus Addendum under this Section 8.3 upon the provision to the other party (referred to for convenience as the
"non-withdrawing party") of [***], specifying in reasonable detail the basis on which the withdrawing party is unilaterally terminating this West Nile Virus
Addendum. (The notice of intent to withdraw described in this Section 8.3 is referred to for convenience as the "withdrawal notice"; and a date which [***] later is
referred to for convenience as the "effective date of withdrawal").

19

---



20

---



9.Escalation.



10.No Other Amendment.Except as expressly set forth in this West Nile Virus Addendum, all other terms and
conditions of the Agreement, the parties' Definitive Written Settlement Agreement, dated December 5, 2001, and the Short Form Agreement, dated November 16, 2001, are hereby ratified and
shall continue in full force and effect. In the event of a conflict between the terms of this West Nile Virus Addendum and the Agreement, the terms of this West Nile Virus Addendum shall control. The
provisions of this West Nile Virus Addendum are intended to, and hereby, supercede any provisions in the Definitive Written Settlement Agreement entered into by and between the parties, dated
December 5, 2001, and the Short Form Agreement entered into by and between the parties, dated November 16, 2001, on the same subject matter.

11.Counterparts.This West Nile Virus Addendum may be executed in counterparts, each of such shall be deemed an
original, and all of which together shall constitute one and same instrument.

21

---

IN
WITNESS WHEREOF, the parties have caused this West Nile Virus Addendum to be executed and the persons signing below warrant that they are duly authorized to sign for and on behalf of
the respective parties.

|GEN-PROBE INCORPORATED,
a Delaware corporation |  | CHIRON CORPORATION,
a Delaware corporation
|---------------------------------------------- |  | ------------------------------------------
|By:                                            |  | /s/HANK NORDHOFF                          
|Its:                                           |  | President; CEO                            
|Date:                                          |  | Oct. 21, 2003                             

22

---

Schedule 1.4A

WNV Development CostGen-Probe

[***]

[***]

[***]

[***]

---

Schedule 1.4B

WNV Development CostChiron

[***]

[***]

---

Schedule 1.17.

Description of WNV Assay Product

The WNV Assay Product is an in vitro nucleic acid amplification test for the qualitative detection of West Nile Virus in human plasma for use in the Blood
Screening Field. The WNV Assay Product is to be developed to run initially on the Procleix semi-automated instrument (eSAS).

---

Schedule 5

WNV Development Costs

1.     Reimbursable
FTE Rate. Budgets for future years will be based on $[***] per FTE per calendar until the budget for the year in question is
finalized each year per Section 5.2.1(b). Until each years budget is agreed upon [***] budget payments per Section 5.3.2 will be based upon the previous years
agreed rate per Section 5.2.1(b) subject to true-up once new rates have been agreed.

2.     WNV
Development Costs included within FTE Labor Rate. WNV Development Costs included within FTE Labor Rate consist of all attributable costs associated with the
development of the WNV Assay Product and modifications to associated instrument system platforms (but excluding Tigris instruments) that may be required for such WNV Assay Product (calculated in
accordance with United States generally accepted accounting principles, or as otherwise mutually agreed in writing between the parties) incurred prior to the Completion Date and includes pilot
development; validation studies necessary for product and process licensure; clinical studies; licensing activities; and the manufacture and ultimate disposition of conformance lots of material,
calculated as follows:



---



3.     WNV
Development Costs not included within FTE Labor Rate.



---



Schedule 5.2.3

WNV Development Costs Calculation Methodology

[***]

[***]

---

Schedule 5.3.1

Accrued WNV Development Costs

[***]

---

Schedule 5.3.2

[***] Budgeted Payments

The party with the negative delta shall submit to the other party, on or before the end of the [***] during the term of the WNV
Development Program, an invoice setting forth the amount of the delta. In addition, any party owed by other an excess adjustment shall submit to the other party, on or before the end of the
[***] during the term of the WNV Development Program, an invoice setting forth the amount of the excess adjustment, providing reasonable detail for any WNV Development Costs
not previously invoiced and requesting payment of [***] of the total amount. WNV Development Costs by the invoicing party incurred to date and not yet reimbursed as provided
herein, providing reasonable detail for any WNV Development Costs not previously invoiced and requesting payment of [***] of the total amount. Each party shall pay on or before
the date specified therefore on the Technical Plan an amount equal to the lesser of (i) the WNV Development Costs reflected on the invoice submitted to such party on account of such payment
(together with amounts reflected on earlier invoices not previously reimbursed) or (ii) the amount of the payment described on the attached Technical Plan. To the extent that a reimbursement
payment is inadequate to cover the total WNV Development Costs incurred to date by a party, then each party shall carry over the balance to the next subsequent payment(s) until finally reimbursed in
full.

By
way of example, and using hypothetical dollars for actual expenditures, the calculation would operate as follows:

[***]

[***]

[***]

[***][***]

[***]



[***][***]

[***]

[***]

[***]


---

Schedule 5.3.3

[***] True-Up Payments
(sample methodology)

By way of example, and using hypothetical dollars for actual expenditures, the calculation would operate as follows: (true-up payment due to Chiron in
this case):

[***]

[***]

[***]

[***]

[***]

[***]

[***][***]

[***]



[***]

[***]

[***]

[***][***]

[***]

[***]

[***]

[***]



[***]


---

QuickLinks